Search
Atl146e
go.drugbank.com/drugs/DB05191InvestigationalATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.
CYP-001
go.drugbank.com/drugs/DB15739InvestigationalCYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are...
Mosedipimod
go.drugbank.com/drugs/DB12592InvestigationalMosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.
MKC1106-PP
go.drugbank.com/drugs/DB06030ExperimentalMKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM. The plasmid portion is a recombinant plasmid expressing segments of the 2 target antigens, PRAME and PSMA. MKC1106-PP...
NLX-P101
go.drugbank.com/drugs/DB05924ExperimentalNLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients.
TTP889
go.drugbank.com/drugs/DB05131InvestigationalTTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders.
Ceramide NP
go.drugbank.com/drugs/DB14111InvestigationalIt is widely used as a moisturizer in various cosmetic and personal products. Together with ceramide 1, they synergistically improve the skin barrier function in humans [A27232, A27233].
R673
go.drugbank.com/drugs/DB05466ExperimentalThe phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning
V-SARS
go.drugbank.com/drugs/DB15812Investigational[COVID-19 convalescent plasma] is currently being acquired from recovered COVID-19 patients and used as prophylaxis for the virus.
Vevorisertib
go.drugbank.com/drugs/DB21481InvestigationalVevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations